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ABSTRACT. Following our recent reports on the inhibition of the water and glycerol channel 
aquaglyceroporin-3 (AQP3) by the coordination complex [AuIII(1,10-pehanthroline)Cl2] 
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(Auphen), a series of six new Au(III) complexes featuring substituted 1,10-phenanthroline ligands 
(1-6) have been synthesized and characterized. The speciation of the compounds studied in 
buffered solution by UV-Visible spectrophotometry showed that most of the complexes remain 
stable for several hours. Quantum mechanics (QM) studies of the hydrolysis processes of the 
compounds suggest that they are thermodynamically less prone to exchange the chlorido ligands 
with H2O or OH
- compared to Au(III) bipyridyl complexes. Preliminary data on the 
antiproliferative activity against A549 human lung cancer cells indicate that the compounds are 
able to inhibit cell proliferation in vitro. Stopped flow spectroscopy showed that these complexes 
potently inhibit glycerol permeation in human red blood cells (hRBC) through AQP3 blockage. 
The QM investigation of the ligand exchange with methane thiol, used as a model of Cys40 of 
AQP3, was carried out for some derivatives, and showed that the affinity of the compounds’ 
binding for thiols is higher compared to the Aubipy complex ([AuIII(bipy)Cl2]PF6, bipy = 2,2’-
bipyridine). In addition, both non-covalent and coordinative binding of complex 3 [AuIII(5-chloro-
1,10-phenanthroline)Cl2]PF6 to the protein channel has been investigated in comparison to the 
benchmark Auphen and Aubipy using a computational workflow, including QM, molecular 
dynamics (MD) and quantum mechanics/molecular mechanics (QM/MM) approaches. Finally, 
Atoms-in-Molecules (AIM) and Natural Bond Orbital (NBO) analyses corroborate the MD 
predictions providing quantification of the non-coordinative interactions between the compounds 
and AQP3. AQP3 inhibition is the result of protein conformational changes, upon coordinative 
gold binding, which induce pore closure. The importance of non-coordinative adducts in 
modulating the AQP3 inhibition properties of the investigated Au(III) compounds has been 
elucidated, and these interactions should be further considered in the future design of isoform 
selective AQP inhibitors. 
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INTRODUCTION 
Cells require membrane channels, the aquaporins (AQPs), to allow fast permeation of water, 
glycerol and other small solutes, including hydrogen peroxide, across their membranes in response 
to osmotic gradients 1. Therefore, these membrane channels are present in most cell types and play 
crucial roles in human physiology, such as skin hydration and wound healing, fat metabolism and 
urine concentration 2. Notably, AQPs have been correlated to cancer biology and development and 
various different isoforms were shown to be expressed in more than several human cancers and at 
different stages of the disease 3-4. Different isoforms have been linked to various tumour types and 
grades, as well as cancer cellular processes as proliferation, migration and angiogenesis 5-6. 
Therefore, these protein channels have been proposed as emerging drug targets for various 
diseases, including cancer 6-7. 
Structurally, AQP channels are very similar: assembled as tetramers in cell membranes, 
with each monomer forming a hourglass-shaped channel, which is derived from six alpha-helices 
that span across the cell membrane and two semi-helices that meet at the centre of the protein 8. 
The pore’s selectivity to various substrates is determined by its specific structural features: a 
constriction site, 3-4 Å wide, named the aromatic/arginine selectivity filter (ar/R SF), and a second 
selectivity filter composed of two asparagine-proline-alanine (NPA) motifs, highly conserved in 
all AQPs. Solute’s size-exclusion is generally determined by the size of the ar/R SF, which can 
vary slightly among AQPs, depending on the exact amino acid composition of this site, while the 
NPA motifs are responsible for creating a positive dipole moment at the side chains of the two 
asparagine residues, acting as a barrier for charged species 8 9. 
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Solute selectivity varies among the 13 mammalian AQPs described so far and three major 
groups can be identified: i) orthodox aquaporins (AQP0, AQP1, AQP2, AQP4, AQP5, AQP6 and 
AQP8), which are primarily water selective 10, ii) aquaglyceroporins (AQP3, AQP7, AQP9 and 
AQP10), permeable to small uncharged solutes such as glycerol 11 and iii) superaquaporins, 
AQP11 and AQP12, which are permeable to water and glycerol, even though they have lower 
sequence homology with other AQPs and are located in intracellular membranes 12-13.  
Aquaglyceroporins in particular, are known to regulate glycerol content in various tissues, 
such as epidermis or fat, and their role as a glycerol channel has been proposed to be involved in 
skin hydration and wound healing, cell proliferation, lipid metabolism and carcinogenesis 2. 
However, the involvement of aquaglyceroporins in these physiological processes has been mostly 
studied using genetically modified organisms. Thus, in order to validate the various roles of AQPs 
in health and disease, as well as to develop AQP-targeted therapies, the use of selective inhibitors 
in addition to genetic approaches, holds great promise 7. However, none of the reported organic 
small-molecule AQP inhibitors show sufficient isoform selectivity to be seen as suitable 
candidates for clinical development 7, 14-15.  
Recently, Au(III) coordination compounds have been identified as selective 
aquaglyceroporin inhibitors 16. In 2012, we were the first to report on the potent and selective 
inhibition of human AQP3 by a series of Au(III) complexes with nitrogen-donor ligands 17-18. The 
compounds could efficiently inhibit glycerol transport through hAQP3 in human red blood cells 
(hRBC), while they were not active on water transport via the orthodox water channel human 
AQP1 17. The most potent inhibitor of the series, Auphen ([AuIII(phen)Cl2]Cl, phen = 1,10-
phenanthroline) had an IC50 in the low micromolar range (0.8 ± 0.08 μM) and was far more 
effective than the benchmark AQPs inhibitor, the mercurial compound HgCl2 
17. In a subsequent 
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study, we examined Auphen capacity of inhibiting cell proliferation in various cell lines, including 
cancerous ones, with different levels of AQP3 expression 19. The obtained results showed a direct 
correlation between AQP3 expression levels and the inhibition of cell growth by the Au(III) 
compound. Furthermore, AQP3 inhibition was observed in the cell lines where proliferation was 
mostly affected by treatment with the gold compound.  
In general, the chemical design of innovative and highly selective inhibitors should be 
supported by structural information on the target AQP protein. When the latter is lacking, as in the 
case of most human aquaglyceroporins, computational methods are essential tools to obtain the 
structure-activity relationships, and several homology models have recently been proposed for 
different AQPs isoforms 20-23. The use of such models is recommended to achieve a deeper 
understanding of the key structural features involved in substrate transport, and helpful to improve 
AQP-targeted drug design. In this context, in the last years, we have conducted a number of studies 
based on molecular modelling approaches and aimed at the elucidation of the molecular 
mechanisms of human AQP3 inhibition by gold compounds. Initially, we investigated the non-
covalent binding of Auphen to AQP3 by molecular docking and observed that the compound’s 
isoform selectivity may be due to the accessibility of Cys40 17. The latter is located at the 
extracellular side of the protein channel and features a thiol group in its side-chain, which is a 
likely candidate for direct binding to Au(III) complexes. The importance of this residue in the 
binding of Auphen to AQP3 was further confirmed by site-directed mutagenesis studies 19. 
More recently, AQP3’s inhibition mechanism by Auphen has been described by us using 
molecular dynamics (MD), combined with density functional theory (DFT) 24. The obtained MD 
results showed that gold-based inhibitors, anchored to Cys40 in AQP3, are able to induce 
shrinkage of the pore preventing substrate permeation. This finding has important implications for 
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future inhibitor design: in fact, other amino acid residues could be targeted, provided that their 
modification leads to the necessary conformational changes to achieve channel closure. Moreover, 
the MD studies showed that binding of the gold compound in one monomer also affects substrate 
permeability in an adjacent one, while altering the overall extracellular distribution of 
hydrophobic/hydrophilic surfaces of the tetramer, which, in turn, may affect the approach of the 
substrates to the pore 24.  
Further investigation of another selective AQP3 inhibitor, the Au(III) cationic complex 
Aubipy [Au(bipy)Cl2]PF6 (bipy = 2,2’-bipyridine) (IC50 = 2.3  0.7 M), bound to the protein 
channel, has been performed by means of a multi-level theoretical workflow including MD and 
quantum mechanics/molecular mechanics QM/MM approaches 25. Thus, the structures of both 
non-covalent and covalent (Cys-bound) Aubipy-AQP3 adducts were studied through the use of 
classical MD simulations to gain a detailed insight into the Aubipy binding and its consequences 
on the AQP3 functionality. In this study, three key aspects for AQP3 inhibition by gold compounds 
emerged: i) speciation of the Au(III) complex prior to protein binding (formation of aquo-
complexes), ii) stability of non-covalent adducts between the compound aromatic ligand and the 
extracellular pore side, and iii) protein conformational changes upon coordinative binding of 
Au(III) ions leading to pore closure, in line with the above-mentioned study on Auphen. 
Considering that Auphen structure is one of the most effective in inhibiting glycerol 
permeation via AQP3 in hRBC and, in order to optimize the compound’s scaffold to improve the 
protein binding and to achieve structure-activity relationships, we have synthesized a new series 
of six Au(III) complexes in which the phenanthroline ligand has been derivatized at different 
positions (1-6, Scheme 1). The compounds have been studied for their AQP3 inhibition properties 
in hRBC by stopped-flow spectroscopy and evaluated for their anticancer properties against the 
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human lung cancer cells A549 in vitro. Initially, the speciation of the gold complexes was studied 
by Quantum Mechanics (QM) calculations in comparison to Auphen and Aubipy. The QM 
investigation of the ligand exchange reaction with methane thiol, used as a model, was carried out 
for Auphen and complexes 2-4. Intrigued by the role of non-covalent with respect to covalent 
metallodrug-AQP3 adducts in the inhibition mechanisms of Auphen and analogues, we applied 
molecular dynamics (MD) simulations to further explore the system at a molecular level for 3 in 
comparison to Auphen. Non-covalent interactions that lead to binding of Auphen and 3 to AQP3 
were further probed using Atoms-in-Molecules (AIM) and Natural Bond Orbital (NBO) analysis. 
Overall, while the Auphen-type complexes feature similar mechanism of AQP3 inhibition, 
important differences were evidenced with respect to the bipyridyl complex Aubipy, in line with 
the observed variations in the experimental inhibition potency of the compounds. 
 
RESULTS AND DISCUSSION 
Synthesis and Characterization 
The synthesis of a series of Au(III) phenanthroline-based complexes 1-6 was achieved by 
coordination reaction of phenanthroline derivatives functionalized in various positions with 
different functional groups (methyl, phenyl, chloro, nitro) with a Au(III) precursor (Scheme 1). 
Some of the Au(III) complexes (2,26-27 4 28-30 and 6 27, 29) were already described in the literature, 
but with different counter ions other than PF6. All the chosen phenanthroline ligands were 
commercially available. The formation of the Au(III) complexes proceeds in one step by reaction 
between 1 eq. of phenanthroline ligand dissolved in acetonitrile and 1 eq. of Au(III) precursor salts 
(NaAuCl4 or KAuCl4) dissolved in water with an excess (3 eq.) of KPF6. The reactions were 
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complete in a few hours at reflux with precipitation of the product. The obtained pale to dark 
yellow powders were then characterized by multinuclear 1D and 2D NMR spectroscopy (See 
Experimental Section and Supplementary Information Figures S1-S18), high-resolution mass 
spectrometry, UV-Visible and infrared spectroscopies. Notably, interpretation of the 1H NMR 
spectra of all the complexes confirmed the coordination of the phenanthroline derivatives to the 
Au(III) ion as a downfield shift of up to 0.7 ppm was noticed for all proton signals of the complexes 
in comparison with the initial ligands. 31P and 19F NMR spectra also confirmed the presence of the 
PF6
- counter ion in the final products, with the presence of a doublet and a heptuplet in 19F and 31P 
NMR spectra, respectively.  
 
Scheme 1. General scheme for the synthesis of complexes 1-6 and related yields. 
Stability in physiological medium 
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addition of 2 eq. of the, physiologically relevant reducing agent, glutathione (GSH) per equivalent 
of Au(III) complex. Thus, the absorbance of the solutions was measured between 275 and 700 nm 
at regular time intervals during 24 h at room temperature, allowing the monitoring of possible 
transformations such as hydrolysis, reduction and/or precipitation of the complexes. The results 
are shown in Figures S19-S24 in the supplementary material. All six complexes exhibit intense 
transitions in the 300-400 nm range, characteristic of the Au(III)-containing chromophore, that 
may be straightforwardly assigned as LMCT (Ligand to Metal Charge Transfer) bands. In these 
cases, spectral changes are observed with time that might be related to the occurrence of partial 
hydrolysis processes of the chlorido ligands. Instead, spectra of complexes 4 and 6 show a marked 
decrease in intensity of the LMCT bands characteristic of the Au(III) phenanthroline chromophore 
(Figures S22 and S24), which in both cases goes in parallel to the formation of a precipitate. We 
hypothesize that initially hydrolysis of the chlorido ligands takes place as for the other derivatives, 
followed by reduction of the Au(III) centre to Au(I) or Au(0). However, formation of colloidal 
gold could not be observed in all cases, which should have resulted in the appearance of a broad 
absorption band around 550 nm. Further characterization of the insoluble products should be 
achieved to exclude possible Au(III) reduction processes and to fully characterize the pathways to 
such extensive decomposition.  
Aquaporin inhibition 
The compounds were tested for their ability to inhibit AQP1 and AQP3 by stopped flow 
spectroscopy using human red blood cells (hRBC), as described previously 17. All the complexes 
showed to selectively inhibit AQP3 glycerol permeability PGly, with IC50 values in the sub-
micromolar level, being similar or even lower than Auphen (Table 1). As expected, the tested 
compounds did not show any inhibitory effect on AQP1 water permeability, as previously reported 
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for Auphen (data not shown). The most potent inhibitory effect was detected for complexes 
featuring substituents in position 5 of the phenanthroline ligand, with compound 4 being the most 
active (IC50 of 0.43  0.08 M) followed by 2 and 3, as represented in Figure 1. 
 
Figure 1. Representative IC50 curve for the inhibition of glycerol permeation of AQP3 by the 
Au(III) complexes Auphen and 2-4. 
 
Table 1. Glycerol permeation inhibiting effects (IC50 values) of various Au(III)-phenanthroline 
complexes (Auphen, 1-6) and the Au(III) bipyridine complex Aubipy in hRBC after 30 min 
incubation. N = number of independent experiments. 
Complex IC50 (M)a 
Auphen 0.80  0.08 
Aubipy 2.3  0.7 
1 0.73  0.09 
2  0.57  0.04 (N = 2) 
3  0.57  0.07 (N=2) 
4  0.43  0.08 
5 0.83  0.01 (N=1) 
6 0.89  0.14 
a
 Values represented as mean ± SEM of at least three independent experiments, unless otherwise stated. 
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Antiproliferation assays  
The antiproliferative properties of complexes 1-6 were evaluated using the classical MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay, after 72 h of treatment, 
against the human lung cancer cell line A549, which expresses AQP3 32. Overall, the complexes 
displayed strong antiproliferative properties, with EC50 values in the low micromolar range (Table 
S1). Specifically, complexes 4 and 5 were found as potent as the benchmark Auphen with EC50 
values of ca. 1 M. The ligands induced antiproliferative effects similar to their corresponding 
complexes (Table S2), in line with previously reported results 33-34, suggesting that the observed 
effect of the complexes could also be due to the release of ligand itself over time. Thus, the 
obtained results may suggest that the compounds are not ideal for further development as 
anticancer agents, unless the control of their speciation will be achieved (e.g. via the use of drug 
delivery systems). Nevertheless, the Au(III) complexes could still be used as chemical probes to 
study AQP3 function in cells benefiting of their isoform selectivity. 
 
Correlation of AQP3 inhibition with DFT-calculated properties of Au(III) compounds 
The structural features of Auphen and 1-6 complexes, expected to exert a major control 
on their reactivity with Cys40 side chain (i.e. presumed to be their coordinative binding site on 
AQP3) were calculated by means of DFT approaches. Indeed, the HOMO-LUMO gap and the 
charge on the Au metal center are connected to the orbital and charge control, respectively, in the 
reaction with nucleophiles. Thus, modulation of these electronic factors may be exerted by the 
presence of different substituents on the phen scaffold. The correlation of glycerol permeation 
 12 
activity as log10(1/IC50) with DFT-calculated properties of Au(III) complexes was then examined, 
including the energy of frontier orbitals (EHOMO and ELUMO) and their difference (Egap), the partial 
charge on metal center (q(Au)), as well as the molecular dipole and volume (Table S3). In general, 
a poor correlation between calculated properties and experimental data was detected (Table S4), 
although we noticed a slightly higher correlation of log10(1/IC50) with qAu, dipole, and volume 
compared to the other properties. However, it seems clear that the dependence of in vitro activity 
on molecular structure is not straightforward, prompting us to carry out more detailed calculations 
on speciation and binding to potential biological targets. 
 
Speciation Study by Quantum Mechanics 
The speciation of gold complexes was further studied by QM calculations. Specifically, 
investigation of the aquation processes of the most active complexes as AQP3 inhibitors, namely 
2, 3 and 4, was carried out by using the computational procedure and decomposition scheme 
described elsewhere 25, and compared with those of Auphen and Aubipy (see Experimental 
section for details). The obtained results showed that, as already stated for Aubipy 25, the 
speciation of Auphen-like species is determined by a hydrolysis process followed by diffusion-
controlled and quantitative deprotonation of the bound water molecules  – negative free energy 
values (Table 2) – leading to only three possible species in water solution: dichloro, chloro-
hydroxo, and dihydroxo species. The estimation of both reaction and activation free energies was 
carried out by decomposing these processes as depicted in Scheme 2. The calculated activation 
free energy for either first or second aquation of the Auphen-like complexes resulted to be quite 
similar to that of Aubipy, with the highest difference in the order of 5 kJ/mol (Table 2). However, 
such differences are within the accuracy limit expected for density functional theory estimation of 
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activation barriers (about 8 kJ/mol). Therefore, our computational model indicates a similar 
hydrolysis rate for all considered Au(III) complexes. The only exception is represented by the 
appreciably lower activation free energy for the second aquation of 4, caused by the particularly 
low free energy contribution for step 1 (Scheme 2), i.e. –0.8 kJ/mol which is about 30 kJ/mol less 
compared to the other Auphen-like complexes.  
 
 
Scheme 2. Reaction decomposition scheme for the hydrolysis of one of the chlorido ligands in 
Auphen, i.e. first aquation. R = reactants, RA = reactant adduct, TS = transition state, PA = product 
adduct, P and P’ = products before and after deprotonation, respectively. 
 
Table 2. Reaction free energy parameters for the first (I) and second (II) aquation of Au(III) 
complexes. All values in kJ/mol. 
Complex 𝛥𝐺𝐼
0 𝛥𝐺𝐼𝐼
0  𝛥𝐺𝐼
± 𝛥𝐺𝐼𝐼
± 
Aubipy 44 63 118 103 
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Auphen 77 86 124 126 
2 67 87 117 121 
3 73 84 122 124 
4 77 57 122 94 
 
 
On the other hand, calculations indicated that both first and second aquation of Auphen-
like complexes are thermodynamically less favored than Aubipy (Table 2). The overall reaction 
free energy for the first and second aquation of Auphen is higher by 23 and 20 kJ/mol, 
respectively, and such differences are essentially maintained in the case of the other Auphen-like 
scaffolds. The only exception is represented by the second aquation of 4, which is conversely 10 
kJ/mol lower in comparison with Aubipy. It is worth mentioning that the estimated 
thermodynamic constants for the first and second aquation of the gold complexes were calculated 
assuming to be in water, at pH 7.4 ([H+] = 3.98×10–8 M) and a constant chloride concentration 
([Cl–] = 100 mM). Therefore, according to the obtained results, we can infer that, in physiological 
conditions, the Auphen-like complexes are prevalently in the dichloro form, presumed to bind at 
the extracellular pore of AQP3. This result highlights a significant difference with respect to 
Aubipy, the latter having been predicted to bind AQP3 in the corresponding chloro-hydroxo form 
25. 
The decomposition of the calculated standard free energy values for either Aubipy and 
Auphen first aquation evidenced that the only significant difference between these complexes is 
detected on step 2 (Scheme 2) which is 26 kJ/mol more endergonic for Auphen (Scheme 3). By 
breaking down step 2 energy it is clearly evidenced that this value is gained by the summation of 
a positive gas phase term plus a negative solvation term in both Aubipy and Auphen. In fact, in 
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spite of the less favorable gas phase term, the solvation term in Aubipy is much lower than in 
Auphen, i.e. by about -52 kJ/mol, thus making step 2 of Auphen aquation more endergonic (Table 
S5). 
 
Scheme 3. Free energy profiles of the first aquation (I) of Aubipy (red) and Auphen (blue). All 
values in kJ/mol. 
 
Quantum Mechanics Study of Binding to Thiols  
To further investigate why the gold complexes have different AQP3 inhibitory effects, and 
assuming Cys40 as the gold binding site as in the case of Auphen, the QM investigation of the 
ligand exchange with methane thiol, used as a model, was carried out for Auphen and complexes 
2-4, all reacting in the corresponding dichlorido form. The decomposition scheme employed for 
aquation (Scheme 2) was similarly applied to the substitution of chloride with thiol; thus, the same 
thermodynamics and kinetics parameters were calculated. The overall activation free energy 
(𝛥𝐺𝑜𝑏𝑠
± ), as well as free energy values for either pre-equilibrium of reactant adduct (RA) formation 
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(𝛥𝐺 𝑠𝑡𝑒𝑝1
0 ) or barrier from RA to PA (𝛥𝐺𝑠𝑡𝑒𝑝2
± ), of Cl– substitution with methane thiol for Auphen 
and 3 are essentially the same estimated for Aubipy, with differences within the expected 
theoretical accuracy. On the other hand, the activation free energies for the reaction with thiol of 
complexes 2 and 4 were lower by about 10-15 kJ/mol (Table S6). In all cases, the pre-equilibrium 
for the formation of RA is endergonic, thus contributing to increase the kinetic barrier for chloride 
substitution, and characterized by free energy values in the narrow range of 29-40 kJ/mol. As 
already reported for Aubipy, 25 the free energy loss for the formation of RA could be compensated 
by the non-coordinative interactions between the gold complex and AQP3 residues, thus, 
kinetically favoring its coordination at the thiol moiety of Cys40 residue. Interestingly, the free 
energy values for the thiol/Cl– exchange of Auphen and complexes 2-4 were lower than the 
corresponding value for Aubipy, thus, indicating that the coordination to thiolate is more favored 
in the Auphen-like complexes. This result is in good agreement with the higher glycerol 
permeation inhibition disclosed by Auphen-like compounds ascribable to a higher amount of 
covalently bound AQP3 units compared to Aubipy, when equilibrium is reached.  
 
Molecular dynamics (MD) simulations of the binding to AQP3 
In order to further corroborate the above-mentioned hypothesis of the importance of non-
covalent interactions to determine the selectivity of AQP3 binding by gold complexes, we applied 
classical MD simulations to further investigate the gold complex/protein adduct. The quaternary 
structure of AQP3 was prepared via homology modelling, following an approach previously 
described by us and reported in the Experimental section 24-25.  Thus, both non-coordinative and 
coordinative adducts of Auphen and of one of the most active inhibitors, the 5-subsituted-chloro-
phenanthroline complex 3 (IC50 = 0.57  0.07 M), with AQP3 were simulated in the Amber force 
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field to sample a set of representative configurations of each system. The obtained results were 
compared with the previously reported ones for Aubipy 25.25 This approach evidenced the effects 
of varying the nitrogen donor ligand scaffold (from phen to bipy) on the AQP3-binding mode of 
the Au(III) complexes, as well as the effects of the substitution in position 5 of the phen ligand.  
The input structures of either NCA or CA structure of Auphen and 3 were obtained via 
superimposition of metal center on the corresponding Aubipy-AQP3 complexes. The 
representative conformations obtained by the end of the workflow encode the structural features 
disclosed by the system, including the effects of thermal motion, and allowed to significantly 
enhance the a posteriori QM analyses of the electronic structure of non-coordinative adducts (vide 
infra). The coordinative adducts of both Auphen and 3 displayed geometrical parameters that 
resemble the corresponding structures of the Aubipy-AQP3 system, although some differences 
between Auphen and 3 were unveiled (Figure 2). Specifically, Auphen is slightly more buried 
inside the pore than 3. This feature allowed establishing a T-shape contact of the phen moiety of 
Auphen with Phe63, which was not detected in the case of 3. The water exposure of the two 
compared scaffolds is also slightly different, with Auphen, in analogy to Aubipy,25 exposing only 
one ring to the solvent, while 3 is exposing a larger portion, i.e. one pyridyl ring plus middle phen 
ring (Figure 2).  
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Figure 2. Most representative coordinative adducts of either Auphen (left) or the [(5-chloro-1,10-
phenanthroline)AuCl2]
+ complex (3) (right) with AQP3, as seen from the extracellular side. The 
positions of Cys40 sulfur atom along the z-axis are labeled (black dashed lines). Metal complex 
and protein carbons are represented in ball-and-stick and colored green and gray, respectively. 
 
A similar impact on both shape and functionality of the AQP3 was evidenced by the 
analysis of Auphen and 3 coordinatively bound complexes. Both adducts compared similarly with 
the corresponding Aubipy system, showing a decrease of the simulated water flux (Table S7). The 
observed decrease of water permeation is caused by conformational rearrangements occurring on 
the side of proximal residues upon the coordinative binding of the gold moiety, in line with 
previously reported studies for another Au(III) complex 24. In particular, the side chain of Arg218, 
forming the selectivity filter (ar/R SF) of AQP3, adopts a folded conformation in the coordinative 
complex, while being much more flexible in the unbound AQP3, as elsewhere reported for Aubipy 
25. Indeed, rather strong hydrogen bond interactions between the guanidine group of Arg218 and 
the AQP3 backbone were detected in both Auphen and 3 coordinative complexes (Scheme 4).  
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Scheme 4. A sketch of the hydrogen bond pattern of Arg218 obtained by MD simulation of 
Auphen, 3 and Aubipy 25 coordinative adducts with AQP3. The percentages of trajectory in which 
tiled hydrogen bonds exist are also reported.  
 
MD simulation of the non-coordinative adducts of Auphen and 3 were also performed. Both metal 
complexes were initially placed to resemble the binding pose of the corresponding Aubipy-AQP3 
complex through the superimposition of phen to the bipy moiety of Aubipy reported by Graziani 
et al., and by assuming both Auphen and 3 to interact via π-π stacking between their metallacycle 
and the phenyl ring of Phe136 [See structure B1 in ref. 25]. Notably, while Auphen maintained 
approximately the starting position, compound 3 essentially detached to find interaction with 
AQP3 outside the extracellular entrance of the pore (data not shown). Based on this outcome, the 
starting pose of compound 3 was changed by a 180° rotation along an axis passing through the two 
pyridyl nitrogens, and MD simulation was carried out. In this new initial orientation, compound 3 
roughly maintains its starting position and forms a non-coordinative complex with AQP3 that 
resembles the one formed by Auphen. The most representative poses of both Auphen and 3 non-
coordinative adduct with AQP3 are compared in Figure 3. The results show the two gold 
complexes interacting with residues at the edge of the extracellular pore of AQP3.  In this pose, 
the compounds are on average 11.17 and 11.36 Å (Au-S) apart from Cys-40 (Table S8), which is 
 
 20 
by 3 Å shorter than the one detected in the Aubipy-AQP3 adduct 25. This slightly closer approach 
to the final coordinative site is in agreement with the higher potency of either Auphen or 3 
compared to Aubipy, and it is probably connected to the lower hydrophilicity of the AuCl2 moiety 
that in these complexes is projected inside, i.e. towards the Cys40 position. In fact, MD 
calculations indicate that the complexes interact differently with the surrounding AQP3 residues. 
The Auphen scaffold is involved in stacking interactions with the phenyl ring of both Phe136 and 
Phe208, whereas compound 3 appears to interact with Phe208 and Asn141 mostly through the 
metal center: the phenyl ring of Phe208 is placed within 4 Å from Au, amenable for a π-metal 
interaction, while the backbone C=O of Asn141 is placed with oxygen at only 3.0 Å, thus, 
amenable for an apical interaction with the positive charge on gold (Figure 3).  
Overall, the MD calculations indicate that Auphen and its chloro-derivative 3 are both able 
to form similar coordinative adducts with AQP3 and give rise to similar alterations of the channel 
structure and functionality. Moreover, these species form stable non-coordinative adducts with 
AQP3 mainly through the formation of stacking interactions, although, compared to Aubipy, the 
detected poses of Auphen and 3 appear to be more amenable for the further reaction with Cys40.  
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Figure 3. Representation of non-coordinative adducts (the most representative pose) of Auphen 
(left) and 3 (right) with AQP3 (top). 2D sketches of main non-coordinative interactions detected 
and weights (percentages) of representative poses: the phenyl ring of either Phe136 or Phe208 are 
bold sketched to highlight that they are placed over the phen scaffold.  
 
Non-covalent interactions that lead to binding of Auphen and 3 to AQP3 were further 
probed using Atoms-in-Molecules (AIM) and Natural Bond Orbital (NBO) analysis. 
Representative structures obtained after clustering were minimized using QM/MM, then truncated 
by selecting all amino acids with at least one atom within 3.5 Å. These structures were used to 
carry out DFT single point calculations, the electron density of which was searched for bond 
critical points corresponding to direct contacts between metal complex and amino acids. Two 
Auphen clusters (denoted Auphen.1 and Auphen.2) account for over 90% of frames: Auphen.1 
exhibits two bond critical points (BCPs) corresponding to stacking of the phen ligand with each of 
Phe136 (c = 0.006 and 0.004 au) and Phe208 (both 0.004 au). We also find BCPs for C—H…O 
contacts with backbone of Phe136 and Gly142 (0.004 and 0.007 au, respectively), and for C—
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H…Cl contacts with Phe208 (0.004 x 2 and 0.002 au). Auphen.2 is similar, with BCPs for stacking 
with Phe136 (0.005 au) and Phe208 (0.004 and 0.003), as well as C—H…O interactions with 
Phe136 (0.004 au) and Phe208 (0.007 au), and C—H…Cl contacts with Val43 (0.007 and 0.006 
au), Phe208 (0.006 and 0.004 au). A single C—H…N contact with His154 is also present (0.007 
au). In the case of compound 3, two clusters (denoted 3.1 and 3.2) account for ca. 80% of the 
trajectory. For 3.1, contacts to the phen ligand include -stacking to Phe208 (c = 0.008 au) and 
C—H… to C of Asn141 (0.004 au), along with Au…O=CAsn141 (0.010 au). Phe208 also forms 
stacking interactions with phen in 3.2, two critical points (c = 0.004 and 0.002 au) are located, 
along with a C—H…Cl—Au contact (0.004 au). A C—H…Cl—Au contact (0.004 au) is also 
present with Val47, along with two C—H…O interactions with backbone O=C of Tyr150.  
NBO analysis allows estimate of the strength of these non-covalent interactions through 
second-order perturbation analysis. In Auphen.1, stacking to Phe136 (1.8 kcal/mol) and Phe208 
(2.71 kcal/mol) dominates, with lesser contributions from Gly142 and Gly145 (1.2 and 0.8 
kcal/mol). Interactions are rather stronger in Auphen.2, Phe136 and Phe208 contributing 4.2 and 
4.4 kcal/mol, respectively. Val43 also contributes to binding at 2.9 kcal/mol, as does His154 at 1.4 
kcal/mol. Non-covalent binding in Auphen.1 is predicted to be markedly weaker (6.5 kcal/mol) 
than in Auphen.2 (12.8 kcal/mol). For 3, NBO indicates that in 3.1 the Au…O=CAsn141 interaction 
contributes 11.2 kcal/mol to the non-covalent binding, while -stacking to Phe208 contributes 12.7 
kcal/mol. In 3.2, stacking to Phe208 gives 4.4 kcal/mol of interaction, while Tyr150 contributes 
2.7 kcal/mol to binding. NBO and AIM analyses corroborate the MD predictions by providing for 
quantification of the non-coordinative interactions between Auphen or complex 3 and the residues 
of AQP3 extracellular pore.  
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CONCLUSION 
In this study, we combined biophysical techniques with advanced computational methods 
to elucidate the mechanism of inhibition of AQP3 by Au(III) complexes with phenanthroline 
ligands at a molecular/atomic level. Thus, a new series of six Au(III) complexes featuring phen 
ligands derivatized at different positions was synthesized and characterized for their stability in 
aqueous solution and for their anticancer effects in vitro. Inhibition of glycerol permeation via 
AQP3 was assessed for each Au(III) compound in hRBC by stopped-flow spectroscopy. Some of 
the new derivatives showed AQP3 inhibition properties which outperformed the benchmark 
compounds Auphen and Aubipy. Our calculations evidenced how the examined Auphen-like 
complexes and Aubipy share several binding properties, although a few relevant differences were 
unveiled. According to QM studies, in physiological conditions, Auphen-like compounds are 
stable in the dichloro form while, as previously ascertained,25 Aubipy is prevalently in the form 
of chloro-hydroxo. This different speciation mostly affects the non-coordinative interaction with 
AQP3. In fact, both Auphen and 3 bind at the extracellular pore side similarly to Aubipy, but 
accessing different residues and with a different orientation. Although the non-coordinative 
interaction energy is about 40 kJ/mol in either cases, Auphen-like complexes project their metal 
moiety towards the side chain of the gold binding site Cys40, and at a shorter distance compared 
to Aubipy. This observation indicates that these compounds can more easily reach their final 
coordinative site. This evidence is also consistent with the higher inhibition of glycerol permeation 
by Auphen and 3 with respect to Aubipy. Combined MD-QM/MM corroborated this view. 
Furthermore, our results show that both Auphen and 3 form coordinative adducts with AQP3 that 
are structurally similar to the one formed by Aubipy, inducing protein conformational 
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rearrangements – as particularly evidenced by the hydrogen bond pattern of the Arg218 side chain 
– which eventually lead to pore closure (AQP3 inhibition). Overall, our results constitute an 
important basis for the future design of gold-based inhibitors selectively targeting different AQPs 
isoforms.  
EXPERIMENTAL SECTION 
The experimental section of this paper can be found in the supplementary information available 
and includes general information, synthesis and characterization of the Au(III) complexes, 
protocols of UV-Visible spectroscopy, aquaporin inhibition studies by stopped-flow spectroscopy 
and antiproliferative assays. In addition, information on DFT studies, MD and QM/MM 
calculations are provided. 
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Table of contents synopsis 
A series of six new Au(III) coordination compounds with phenanthroline ligands have been 
synthesized and studied for the inhibition of the water and glycerol channel aquaporin-3 (AQP3). 
Combining different experimental and computational approaches, further insights into the 
mechanisms of AQP3 inhibition by gold compounds at a molecular level has been gained.  The 
results evidence the importance of non-coordinative adducts formation, prior to 'covalent' protein 
binding, to achieve selective AQP3 inhibition.  
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